Ajinomoto Althea, Inc., announced a GMP production suite in newly established High Potency
Products (HPP) manufacturing site located in San Diego, California, in September 2017. Currently,
Althea is offering process development and analytical services to the clients and from November
2017, the company will provide facilities for GMP manufacturing of bioconjugation and complex
formulation. Apart from this services, Althea is aiming to provide full manufacturing services
including fill-and-finish, which will start off in 2018.
Key Players:
The key players in biopharmaceutical contract manufacturing market include
• Lonza Group Ltd.,
• ProBioGen AG,
• Boehringher Ingelheim,
• BIOMEVA GmbH,
• Celonic GmbH,
• Sandoz,
• Fujifilm Diosynth Biotechnology,
• Rentschler Biotechnologie.
Request For Customization @ https://www.coherentmarketinsights.com/insight/request-
customization/1077
Global Biopharmaceutical Contract Manufacturing Market Taxonomy:
On the basis of contract type, product type, and therapeutic application, global biopharmaceutical
contract manufacturing market is segmented into:
By Contract Type:
•Active Pharmaceutical Ingredient (API)
•Fill-And-Finished
By Product Type:
•Interferons
•Monoclonal Antibodies
•Recombinant Hormone
•Proteins
•Vaccines
•Vitamins
•Insulin
•Others
By Therapeutic Applications:
•Oncology